Glycolysis and the Pentose Phosphate Pathway Promote LPS-Induced NOX2 Oxidase- and IFN-β-Dependent Inflammation in Macrophages.

LPS NADPH oxidase NOX2 glycolysis inflammation macrophages pentose phosphate pathway reactive oxygen species

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
29 Jul 2022
Historique:
received: 17 06 2022
revised: 26 07 2022
accepted: 26 07 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Macrophages undergo a metabolic switch from oxidative phosphorylation to glycolysis when exposed to gram-negative bacterial lipopolysaccharide (LPS), which modulates antibacterial host defence mechanisms. Here, we show that LPS treatment of macrophages increased the classical oxidative burst response via the NADPH oxidase (NOX) 2 enzyme, which was blocked by 2-deoxyglucose (2-DG) inhibition of glycolysis. The inhibition of the pentose phosphate pathway with 6-aminonicotinamide (6-AN) also suppressed the LPS-induced increase in NOX2 activity and was associated with a significant reduction in the mRNA expression of NOX2 and its organizer protein p47phox. Notably, the LPS-dependent enhancement in NOX2 oxidase activity was independent of both succinate and mitochondrial reactive oxygen species (ROS) production. LPS also increased type I IFN-β expression, which was suppressed by 2-DG and 6-AN and, therefore, is dependent on glycolysis and the pentose phosphate pathway. The type I IFN-β response to LPS was also inhibited by apocynin pre-treatment, suggesting that NOX2-derived ROS promotes the TLR4-induced response to LPS. Moreover, recombinant IFN-β increased NOX2 oxidase-dependent ROS production, as well as NOX2 and p47phox expression. Our findings identify a previously undescribed molecular mechanism where both glycolysis and the pentose phosphate pathway are required to promote LPS-induced inflammation in macrophages.

Identifiants

pubmed: 36009206
pii: antiox11081488
doi: 10.3390/antiox11081488
pmc: PMC9405479
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Health and Medical Research Council
ID : 1122506
Organisme : National Health and Medical Research Council
ID : 1128276

Références

Biomark Insights. 2018 Feb 06;13:1177271918755391
pubmed: 29449774
Mini Rev Med Chem. 2009 Aug;9(9):1084-101
pubmed: 19689405
J Virol. 2014 Mar;88(6):3485-95
pubmed: 24403577
Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents
pubmed: 11585785
Nature. 2013 Apr 11;496(7444):238-42
pubmed: 23535595
J Biol Chem. 2004 Mar 5;279(10):9424-31
pubmed: 14672929
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6
pubmed: 23203888
Cell Rep. 2015 Jul 7;12(1):102-115
pubmed: 26119735
J Pediatr. 1989 Apr;114(4 Pt 1):555-60
pubmed: 2784499
Immunol Lett. 2017 Mar;183:17-23
pubmed: 28130076
Int J Mol Sci. 2012;13(9):10697-721
pubmed: 23109817
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
J Biol Chem. 1961 May;236:1534-43
pubmed: 13692277
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
Free Radic Res. 2014 Aug;48(8):940-7
pubmed: 24869957
Adv Med. 2016;2016:9152732
pubmed: 27774507
Arch Toxicol. 2015 Aug;89(8):1209-26
pubmed: 26047665
Cell. 2016 Oct 6;167(2):457-470.e13
pubmed: 27667687
Redox Biol. 2014 Jan 10;2:206-10
pubmed: 24494194
Clin Sci (Lond). 2016 Apr 1;130(7):479-90
pubmed: 26888560
Cancer Cell. 2005 Jan;7(1):77-85
pubmed: 15652751
Nat Rev Immunol. 2019 May;19(5):291-304
pubmed: 30679807
Front Cell Neurosci. 2017 Jan 10;10:301
pubmed: 28119569
Antioxid Redox Signal. 2014 Jan 10;20(2):281-94
pubmed: 24053613
Free Radic Biol Med. 2011 Sep 1;51(5):978-92
pubmed: 21627987
Nat Commun. 2017 Jul 12;8(1):69
pubmed: 28701733
Oxid Med Cell Longev. 2017;2017:3496043
pubmed: 28255425
Nat Rev Immunol. 2016 Sep;16(9):553-65
pubmed: 27396447

Auteurs

Jonathan R Erlich (JR)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

Eunice E To (EE)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.
F.M. Kirby Neurobiology Centre, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Raymond Luong (R)

Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton 3800, Australia.

Felicia Liong (F)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

Stella Liong (S)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

Osezua Oseghale (O)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

Mark A Miles (MA)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

Steven Bozinovski (S)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

Robert D Brooks (RD)

Clinical and Health Sciences, University of South Australia, Adelaide 5001, Australia.

Ross Vlahos (R)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

Stanley Chan (S)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

John J O'Leary (JJ)

Discipline of Histopathology, School of Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, D08 XW7X Dublin, Ireland.
Sir Patrick Dun's Laboratory, Central Pathology Laboratory, St James's Hospital, D08 XW7X Dublin, Ireland.
Emer Casey Research Laboratory, Molecular Pathology Laboratory, The Coombe Women and Infants University Hospital, D08 XW7X Dublin, Ireland.
CERVIVA Research Consortium, Trinity College Dublin, D08 XW7X Dublin, Ireland.

Doug A Brooks (DA)

Clinical and Health Sciences, University of South Australia, Adelaide 5001, Australia.
Discipline of Histopathology, School of Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, D08 XW7X Dublin, Ireland.

Stavros Selemidis (S)

School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia.

Classifications MeSH